Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Gilberto De Lima Lopes Jr.

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1151-9903; OpenAlex author ID A5068401391, A5110575336. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma Last author DOI 10.64898/2026.09.16.26363246↗
  2. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Co-author DOI 10.1007/s00280-014-2414-z↗
  3. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. First author DOI 10.1097/coc.0b013e3182436e8c↗
  4. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e31821862fb↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peter J. Hosein · 2 shared papers, 2013–2026 · strength 0.42
  2. Sunwoo Han · 1 shared paper, 2026 · strength 0.39
  3. Gretel Terrero · 1 shared paper, 2026 · strength 0.39
  4. Jessica MacIntyre · 3 shared papers, 2012–2014 · strength 0.10
  5. Jaime Rafael Merchan · 3 shared papers, 2012–2014 · strength 0.10
  6. Caio Rocha‐Lima · 2 shared papers, 2012–2014 · strength 0.07
  7. Soley Bayraktar · 1 shared paper, 2014 · strength 0.04
  8. Heloisa Prado Soares · 1 shared paper, 2014 · strength 0.04
  9. Alberto J. Montero · 1 shared paper, 2013 · strength 0.03
  10. Caio M. Rocha Lima · 1 shared paper, 2013 · strength 0.03
  11. Danny Sleeman · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.